About Mitochon Pharmaceuticals


Mitochon Pharmaceuticals is a start-up biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. The company’s development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s, Batten Disease, Stroke, Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, Parkinson Disease and severe burns, and secondarily on metabolic disorders due to over-nutrition (diabetes, obesity and NASH). On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies.

visit | email 

Key People


Robert Alonso
CEO


John Geisler
CSO


Peter Crooks, Ph.D.
SVP of Chemistry